SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed
Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, nsomniyak, bUrRpPPP!, runncoach, kld2
Search This Board: 
Last Post: 7/21/2017 3:02:01 PM - Followers: 70 - Board type: Free - Posts Today: 0

NTRPD Security Details
Share Structure


Market Value1 $45,774,160 a/o Jan 18, 2017
Authorized Shares 12,500,000 a/o Jan 12, 2017
Outstanding Shares 6,781,357 a/o Jan 12, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 1,627,372 a/o Jan 12, 2017

COMPANY PRESENTATION

http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Neurotrope%20%20100516.pdf

Top line Phase 2 study results expected to be released in April 2017The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million

 

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients.  The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI).  Top line results from the study are expected to be announced in April 2017.  Patients meeting the MMSE enrollment criteria score of 4-15 were enrolled in the study.  Two doses of bryostatin, 20ug and 40ug, vs. placebo for 12 weeks are being tested.  A total of 148 patients were enrolled into the study. 

The Company also announced that it has raised an additional $4.3 million in a final closing of its private placement in addition to the approximately $20.2 million raised and previously announced in a press release on Friday, November 18, 2016.

"Completion of enrollment in this study marks a significant milestone for Neurotrope, as well as the Alzheimer's community, as we take another step toward advancing what we believe could be the first potential new treatment for people with Alzheimer's disease in more than 15 years, and we believe would be the first one targeting causes of the symptoms, lost synaptic networks, and not just providing transient symptomatic relief," said Dr. Daniel Alkon, MD, Neurotrope's President and Chief Scientific Officer.  "Other companies targeting this disease are enrolling mildly impaired patients. We targeted the more severe patient population because of our experience with severe patients through our compassionate use studies. Those studies suggested reversal of some of the manifestations of the disease."

"Bryostatin's multi-modal mechanism of action not only targets the neuronal deficits of AD but also synaptic deficits.  This combined mechanism of action through PKC epsilon activation gave the Company the confidence to commit to these trials in moderate to severe patients," said Dr. Susanne Wilke, PhD., the Company's Chief Executive Officer.  "We believe that we may have a breakthrough in Alzheimer's disease and other neurological disorders. With the recently completed financing, we believe that we are in a strong position to negotiate terms with pharmaceutical partners."

Josh Silverman, Chairman of the Company, added, "We are pleased with the investor response to our new management team and the excitement surrounding our upcoming clinical data.  We raised more money than anticipated and plan on investing our capital efficiently in our continuing effort to increase shareholder value while making a difference in treating neurological disorders."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Neurotrope has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock underlying the warrants purchased in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes and a by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.  

Neurotrope is also conducting preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Neurotrope has exclusively licensed technology from Cognitive Research Enterprises (formerly named the Blanchette Rockefeller Neurosciences Institute) for Alzheimer's disease therapeutics and Fragile X Syndrome and has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease. 

Trial details 
NTRP Security Details
 
 
 
 
 
 
NTRP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP News: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017 07/19/2017 11:36:00 AM
NTRP News: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017 07/19/2017 11:16:00 AM
NTRP News: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting 06/29/2017 09:30:00 AM
NTRP News: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Neurotrope, Inc. Shareholders & a Lead Plaintiff De... 06/06/2017 11:51:00 AM
NTRP News: The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Neurotrope, Inc. Shareholders & a Lead Plaintiff D... 06/05/2017 02:16:00 PM
PostSubject
#4967  Sticky Note Full 2a trial article. Some incredible and runncoach 05/15/17 05:57:37 PM
#4691  Sticky Note NEUROTROPE Announces Positive Top-Line Results From Phase 2 bUrRpPPP! 05/02/17 03:05:10 PM
#1870  Sticky Note NTRP has updated their Company presentation on their website: SF Wolf 03/14/17 08:33:06 AM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#5325   I agree. Many investors, myself included, hoped runncoach 07/21/17 03:02:01 PM
#5324   I think the reason for the fall in MaxTok 07/21/17 01:48:45 PM
#5323   How Close Are We to Finding a bzlegendz 07/21/17 12:10:07 PM
#5322   What we have with NTRP is the opposite MaxTok 07/21/17 10:57:04 AM
#5320   17 week data. runncoach 07/20/17 04:21:13 PM
#5319   Very much doubt it, no reason probably a Whatsupp 07/20/17 11:42:24 AM
#5318   You mean a year or more down the runncoach 07/20/17 11:39:04 AM
#5317   That would figure - more cheap shares and XenaLives 07/20/17 11:31:29 AM
#5316   Haven't heard that. Could explain price action I runncoach 07/20/17 08:59:55 AM
#5315   I'm guessing seldom to scams voluntarily go through runncoach 07/20/17 08:44:30 AM
#5314   Just heard that a $3 mil private placement MaxTok 07/20/17 08:30:40 AM
#5313   So many calling fraud and spreading misinformation on Wildginger 07/20/17 08:22:12 AM
#5312   I'm not sure. Bryostatin was only given runncoach 07/20/17 08:02:57 AM
#5311   Is there no 17 wk data then? Wildginger 07/20/17 07:53:24 AM
#5310   What they now need to do IMO is runncoach 07/19/17 07:03:32 PM
#5309   It explicitly states just that on slide 22 fyi. runncoach 07/19/17 04:11:32 PM
#5308   First read is you are correct. There runncoach 07/19/17 03:35:42 PM
#5307   There is a clear signal. New mechanism Biostudent 07/19/17 03:22:50 PM
#5306   The FDA process is not "rigid", in fact XenaLives 07/19/17 02:57:30 PM
#5305   Bryo is poison Bearly Bullish 07/19/17 02:57:26 PM
#5304   Seems to me like they have a simple MaxTok 07/19/17 02:36:28 PM
#5303   Additional studies warranted Bearly Bullish 07/19/17 02:07:33 PM
#5302   They need to first bring a drug to MaxTok 07/19/17 12:55:30 PM
#5301   No indication of intent to treat earlier stage patients. XenaLives 07/19/17 12:47:09 PM
#5300   Seems like the 20 m dose has a MaxTok 07/19/17 12:27:18 PM
#5299   Is there more data to be released? Measured 07/19/17 12:23:49 PM
#5298   Safety + effect size = failure Bearly Bullish 07/19/17 12:12:26 PM
#5297   Great lol. No wonder market isn't happy runncoach 07/19/17 12:07:48 PM
#5296   Basically what the May pr should have looked Wildginger 07/19/17 12:05:58 PM
#5295   Going to be awhile before I get a runncoach 07/19/17 11:57:02 AM
#5294   I'm no expert, but seems like the data MaxTok 07/19/17 11:55:14 AM
#5293   Thoughts anyone ? MaxTok 07/19/17 11:40:46 AM
#5292   Here is presentation. Whatsupp 07/19/17 11:34:13 AM
#5291   http://www.prnewswire.com/news-releases/neurotrope-presents-phase-2-data-assessi MaxTok 07/19/17 11:31:21 AM
#5290   Heard there is a PR. Can't find it. MaxTok 07/19/17 11:27:58 AM
#5289   The embargo ends at the start of the Whatsupp 07/19/17 11:20:15 AM
#5288   I have no idea. Knee-deep in my real runncoach 07/19/17 11:18:13 AM
#5287   Do you know what the protocols are in MaxTok 07/19/17 11:17:03 AM
#5286   Heard that the abstracts can only be released MaxTok 07/19/17 11:15:18 AM
#5285   No abstract? Link? blu_1 07/19/17 11:13:45 AM
#5284   Big presentation, would be nice if someone would MaxTok 07/19/17 11:13:43 AM
#5283   any poster yet McMagyar 07/19/17 11:12:00 AM
#5282   Not live I dont think runncoach 07/19/17 11:04:51 AM
#5281   Is there a live stream for this presentation? MaxTok 07/19/17 11:03:55 AM
#5280   I agree with that. That's the thing runncoach 07/18/17 05:35:58 PM
#5279   Max, I agree with you. What I think Whatsupp 07/18/17 05:21:08 PM
#5278   What's also interesting to me is why isn't MaxTok 07/18/17 04:46:22 PM
#5277   I'm not sure what to expect as far runncoach 07/18/17 03:28:04 PM
#5276   Coach - layout what you hope to hear Whatsupp 07/18/17 03:07:55 PM
#5275   Yeah I figure they didn't hire someone new runncoach 07/18/17 06:27:06 AM
PostSubject